natgillin/translations-raw huggingface dataset:
Governance (f) to facilitate coordination with national and international activities in this area; (g) to undertake communication and dissemination activities; (h) to communicate and interact with the Member States and the countries associated with the Seventh Framework Programme via a group specifically established for this purpose (hereinafter referred to as the IMI States Representatives Group); (i) to organise at least an annual meeting (hereinafter referred to as a Stakeholder Forum) with interest groups to ensure openness and transparency of the Research Activities of the IMI Joint Undertaking with its stakeholders; (j) to notify legal entities that have concluded a grant agreement (hereinafter referred to as Grant Agreement) with the IMI Joint Undertaking of the potential borrowing opportunities from the European Investment Bank, in particular the Risk Sharing Finance Facility set up under the Seventh Framework Programme; (k) to publish information on the projects, including the name of the participants and the amount of the financial contribution of the IMI Joint Undertaking per participant; (l) to ensure the efficiency of the Joint Technology Initiative on ‘Innovative Medicines’; (m) to carry out any other activity needed to achieve the objectives referred to in Article 2 of the Regulation. 
Vodenje (i) organizirati najmanj en letni sestanek, v nadaljnjem besedilu: forum zainteresiranih strani, z interesnimi skupinami, in tako v razmerju do njih zagotavljati odprtost in preglednost raziskovalnih dejavnosti Skupnega podjetja IMI; (j) obveščati pravne osebe, ki so s Skupnim podjetjem IMI sklenile sporazum o dodelitvi sredstev, v nadaljnjem besedilu: sporazum o dodelitvi sredstev, o priložnostih za posojila pri Evropski investicijski banki, predvsem pri Skladu za financiranje delitve tveganja, ustanovljenem v okviru Sedmega okvirnega programa; (k) objavljati informacije o projektih, vključno z imeni sodelujočih in znesku finančnega prispevka Skupnega podjetja IMI na sodelujočega; (l) skrbeti za učinkovitost skupne tehnološke pobude za „inovativna zdravila“; (m) izvajati vse druge dejavnosti, potrebne za doseganje ciljev iz odstavka 2 te uredbe. (člen 4 Priloge k Uredbi (ES) št. 73/2008 – Statut Skupnega podjetja za izvajanje skupne tehnološke pobude za inovativna zdravila) 1 – Upravni odbor 2 – Izvršni direktor 3 – Znanstveni odbor 4 – Dva svetovalna organa Skupina predstavnikov držav, vključenih v IMI, in forum zainteresiranih strani. 5 – Notranja revizija − notranji revizor Evropske komisije (člen 10 Priloge k Uredbi (ES) št.
(Article 11(4) of Regulation (EC) No 73/2008 and Article 129 of the IMI’s financial rules) Budget The final budget consisted of commitment appropriations of 285 379 570 euro and payment appropriations of 88 898 250 euro. 
73/2008 in člen 129 finančnih pravil Skupnega podjetja IMI) Proračun V končnem proračunu so odobritve za prevzem obveznosti znašale 285 379 570 EUR, odobritve plačil pa 88 898 250 EUR.
These amounts included appropriations carried over from 2010 of 116 862 090 euro in commitment appropriations and of 64 506 677 euro in payment appropriations. 
Ta zneska sta vsebovala odobritve, prenesene iz leta 2010, in sicer 116 862 090 EUR odobritev za prevzem obveznosti in 64 506 677 EUR odobritev plačil.
Staff as at 31 December 2011 31 posts provided for in the establishment plan (26 Temporary Agents + 5 Contract Agents), of which, 31 posts were occupied. 
Število zaposlenih 31. decembra 2011 31 mest v načrtu delovnih mest (26 začasnih in 5 pogodbenih uslužbencev), od tega 31 zasedenih.
Staff: - Temporary Agents: 26 - Contract staff: 6 (one CA was recruited in anticipation in order to cover the maternity leave of one TA) - Seconded National Experts: 0 - Local staff: 0 Allocated to: - Operational activities: 6 - Administrative tasks: 8* - Horizontal tasks: 17 13 Resources available to the Joint Undertaking in 2011 AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 Activities and services provided in 2011 * the number refers to administrative assistants with administrative tasks. 
Uslužbenci: - začasni uslužbenci: 26 - pogodbeni uslužbenci: 6 (en pogodbeni uslužbenec je bil vnaprej zaposlen za nadomeščanje ene začasne uslužbenke na porodniškem dopustu) - napoteni nacionalni strokovnjaki: 0 - lokalni uslužbenci: 0 Ti opravljajo: 12 Viri, ki so bili Skupnemu podjetju IMI na voljo v letu 2011 Dejavnosti in storitve, zagotovljene v * Število se nanaša na administrativne asistente z upravnimi nalogami. Objava ali priprava novih razpisov za zbiranje predlogov, vrednotenje, pogajanja, upravljanje donacij, stalni stiki z upravičenci in drugimi udeleženci ter podpora zanje in njihovo usmerjanje, - - - operativne dejavnosti: 6 upravne naloge: 8* horizontalne naloge: 17 AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012
Launched or prepared for new calls for proposals, evaluation, negotiation, grant management, ongoing contact, support and guidance to beneficiaries and other participants, communication and organisation of meetings and events with key stakeholders, as well as consultations and support to the Founding Members on the innovative medicine research strategy and associated activities. 
letu 2011 komuniciranje in organizacija sestankov in prireditev s ključnimi zainteresiranimi stranmi, kot tudi posvetovanje z ustanovnima članicama o raziskovalni strategiji za inovativna zdravila in povezanih dejavnostih ter podpora ustanovnima članicama.
14 Source: Information supplied by the IMI JU. 
Vir: Podatki, ki jih je posredovalo Skupno podjetje IMI.
AEI003738EN05-12PP-CH205-12APCFIN-RAS-IMI-OR.DOC 13.11.2012 
13 AEI003738SL05-12PP-CH205-12APCFIN-RAS-IMI-TR.DOC 13.11.2012
IMI Joint Undertaking’s reply to the European Court of Auditors on the Report on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year 2011 19 November 2012 Paragraph 15 IMI JU welcomes the positive conclusion of the Court on the legality and regularity of all transactions underlying the annual accounts of the Joint Undertaking with the only exception of material errors detected by IMI JU in relation to interim payments for first call claims. 
Odgovori Skupnega podjetja IMI na poročilo Evropskega računskega sodišča o letnih računovodskih izkazih Skupnega podjetja za pobudo za inovativna zdravila za proračunsko leto 2011 19. november 2012 Odstavek 15 Skupno podjetje IMI pozdravlja pozitivne ugotovitve Sodišča glede zakonitosti in pravilnosti vseh transakcij, povezanih z njegovimi letnimi računovodskimi izkazi; edina izjema so vsebinske napake, ki jih je Skupno podjetje IMI samo odkrilo v zvezi z vmesnimi plačili za zahtevke za povračilo stroškov v okviru prvega razpisa za zbiranje predlogov.
Interim payments in 2011 accounted for 20 % (15,2 million euro) of the total payments paid out by IMI JU in 2011 (74,3 million euro) and 22 % of the total payments made by IMI JU to beneficiaries (69,0 million euro). 
Vmesna plačila v letu 2011 so znašala 20 % (15,2 milijona EUR) skupnega zneska vseh izplačil Skupnega podjetja IMI v letu 2011 (74,3 milijona EUR) oziroma 22 % skupnega zneska plačil, ki jih je to nakazalo upravičencem (69,0 milijona EUR).
In addition, without questioning the Court’s own calculation of the error rate based on IMI JU’s first audits, the detected and residual error rate resulting from these finalised ex-post audits, applying the methodology established in IMI JU’s ex-post audit strategy, were 4,58 % and 3,72 % respectively as at September 2012. 
Če se Skupno podjetje IMI opre na izračun stopnje napake, ki ga je Sodišče samo naredilo na podlagi prvih revizij Skupnega podjetja IMI, sta ugotovljena in preostala stopnja napak, ki izhajajo iz teh dokončnih naknadnih revizij, pri katerih se je uporabila metodologija, določena v strategiji naknadnih revizij Skupnega podjetja, septembra 2012 znašali 4,58 % oziroma 3,72 %.
This result is based on a relatively limited number of concluded audits, and concentrated on new or unaudited beneficiaries from the first IMI projects, where a higher rate of error can be expected. 
Ta rezultat temelji na sorazmerno omejenem številu dokončanih revizij in je osredotočen na nove ali nerevidirane upravičence iz okvira prvih projektov pobude za inovativna zdravila, pri katerih je moč pričakovati višjo stopnjo napak.
2011 was the first complete year of ex-ante and ex-post control with audits being launched as soon as the first costs claims related to Call 1 projects were validated and paid. 
Leto 2011 je bilo prvo polno leto izvajanja predhodnega in naknadnega kontroliranja, saj so se revizije začele izvajati takoj potem, ko so bili potrjeni in izplačani prvi zahtevki za povračilo stroškov, povezani s projekti v okviru prvega razpisa za zbiranje predlogov.
The errors reported by the Court as the basis for a qualified opinion were detected by IMI JU’s own internal control system and this in itself demonstrates the effectiveness of this process. 
Napake, za katere je Sodišče navedlo, da so bile podlaga za mnenje s pridržki, so bile ugotovljene tudi s sistemom notranjega kontroliranja Skupnega podjetja IMI, kar samo po sebi dokazuje učinkovitost tega procesa.
Moreover, the multi-annual basis of IMI JU’s strategy and operations also means that additional time is needed before a full assessment can be made on the impact of such controls. 
Poleg tega večletna podlaga za njegovo strategijo in poslovodenje pomeni tudi, da je potreben dodaten čas, preden se lahko izvede popolna ocena o vplivu tovrstnih kontrol.
IMI JU, nonetheless, acknowledges the risks related to grant management and is taking the appropriate measures both at ex-ante and ex-post level to follow-up and correct the errors detected from the finalised ex-post audits. 
Skupno podjetje IMI kljub temu priznava tveganja, povezana z upravljanjem donacij, in bo zato sprejelo ustrezne ukrepe na predhodni in naknadni ravni, da bo nadalje spremljalo in odpravilo napake, ugotovljene pri dokončanih naknadnih revizijah.
In addition, new initiatives are being introduced with the aim of preventing the occurrence of such errors among existing and new participants of IMI JU projects. 
Hkrati bo uvedlo nove pobude, s katerimi želi preprečiti pojavljanje tovrstnih napak v obstoječih in novih podjetjih, ki sodelujejo v projektih Skupnega podjetja IMI.
These have included the further strengthening of ex-ante controls in order to allow higher detection and correction of errors before validation of cost claims, the organisation of financial workshops and the development of guidance aimed at increasing the awareness and the understanding of participants on key issues such as the eligibility of costs and the importance of keeping adequate supporting documentation linked to the submitted claims. 
To vključuje nadaljnje izboljševanje predhodnih kontrol, da bi s tem lahko bolje odkrivali in popravljali napake pred potrditvijo zahtevkov za povračilo stroškov, organizacijo delavnic na temo finančnih zadev in pripravo smernic za boljšo ozaveščenost sodelujočih o ključnih vprašanjih, kot sta upravičenost stroškov in pomen vodenja ustrezne dokazne dokumentacije, povezane z vloženimi zahtevki, ter njihovo razumevanje teh vprašanj.
This is all the more important as a large portion of participants are small and medium size enterprises and other entities are unfamiliar with EU research programmes. 
To je še toliko pomembneje, ker velik delež sodelujočih predstavlja mala in srednje velika podjetja, drugi pravni subjekti pa niso seznanjeni z raziskovalnimi programi EU.
The budget was based on the adopted Legislative Financial Statements and its execution followed the principles of sound financial management. 
Odstavek 19 Proračun je temeljil na sprejetih zakonodajnih finančnih izkazih, pri njegovem izvrševanju pa so se upoštevala načela dobrega finančnega poslovodenja.
Moreover, none of the funds budgeted for running costs were lost and unutilised funds from the European Commission were transferred to research activities. 
Poleg tega niso bila nobena sredstva, ki so bila v proračunu predvidena za stroške za poslovanje, izgubljena, medtem ko so se neporabljena sredstva od Evropske komisije prenesla na raziskovalne dejavnosti.
It is also important to keep in view that 50 % of the budget for running costs is financed through EFPIA. 
Treba je upoštevati tudi, da se 50 % proračuna za stroške za poslovanje financira prek Evropske federacije farmacevtske industrije in združenj (EFPIA).
Paragraph 21 Effective measures were put in place in 2012 to increase and accelerate the commitment of EU funding and the matching in-kind contributions from EFPIA members through the launch of several Calls for proposals. 
Odstavek 21 Leta 2012 so bili uvedeni učinkoviti ukrepi za povečanje in pospešitev obveznosti financiranja EU ter uskladitev stvarnih prispevkov članov EFPIA z objavo več razpisov za zbiranje predlogov.
To date in 2012, three Calls for Proposals have been launched with another one foreseen by the end of 2012, thus marking significant progress in the execution of IMI programme. 
Do današnjega dne so bili objavljeni trije razpisi za zbiranje predlogov, medtem ko je eden predviden za konec leta 2012, kar pomeni pomemben napredek pri izvajanju programa pobude za inovativna zdravila.
Paragraph 22 The total amount of chapter 30-C2 “Research Agenda” (117 million euro) is the correct amount with the difference being due to a technical problem in the ABAC system which is now being addressed. 
Odstavek 22 Skupni znesek poglavja 30-C2 „Raziskovalni program“ (117 milijonov EUR) je pravilni znesek, a je do razlike prišlo zaradi tehnične težave v sistemu ABAC, ki jo sedaj odpravljajo.
With regard to the authorised carry-over, this is duly clarified in the preamble of the Governing Board Decision whereby it is stated that IMI JU had operational commitments and payment appropriations which had not been used at the end of the financial year 2010 and that it was considered necessary to use the cancelled appropriation during 2011. 
Kar zadeva odobreni prenos sredstev, je to bilo ustrezno pojasnjeno v uvodnih izjavah sklepa upravnega odbora, v katerih je navedeno, da je imelo Skupno podjetje IMI obveznosti za poslovanje in odobritve plačil, ki ob koncu proračunskega leta 2010 niso bile porabljene, in da se je zato menilo, da je treba razveljavljena odobrena proračunska sredstva porabiti v letu 2011.
Nonetheless, IMI JU will clarify the text of the decision for the future carry-overs. 
Kljub temu bo Skupno podjetje IMI pojasnilo besedilo sklepa pri prihodnjih prenosih sredstev.
Paragraph 23 Work related to the formal assessment of the internal control system was carried out by the Internal Control Coordinator in the last quarter of 2011 and finalised through the approval of the report to the Executive Director on 13 February 2012. 
Odstavek 23 Delo, povezano s formalno oceno sistema notranje kontrole, je koordinator za notranjo kontroliranje opravil v zadnjem četrtletju leta 2011, dokončal pa ga je potem, ko je izvršni direktor 13. februarja 2012 odobril poročilo.
This is in line with what is foreseen in Internal Control Standard 15 and in preparation of the Annual Activity Report of 2011. 
To je v skladu s tistim, kar je predvideno v standardu notranjega kontroliranja št. 15, in s pripravami letnega poročila o dejavnostih za leto 2011.
During 2011, the implementation of the internal control systems was also periodically reviewed, in a formal manner, through the preparation and approval of the 2011 Action Plan in February 2011 and through its updating in May and October 2011. 
Leta 2011 je bilo izvajanje sistemov notranje kontrole tudi redno formalno pregledano v obliki priprav akcijskega načrta za leto 2011 februarja 2011 in njegovega sprejetja ter njegove posodobitve maja in oktobra 2011.
Paragraph 24 An Action Plan is being drawn up to address the recommendations of the Accounting Officer of 27 September 2012. 
Odstavek 24 Pripravlja se akcijski načrt, v katerem bodo upoštevana priporočila računovodje z dne 27. septembra 2012.
Paragraph 25 EFPIA members participating in IMI JU projects submitted their first declarations on in-kind contributions in February 2012 following the approval of the methodology by the Governing Board on 11 November 2011. 
Odstavek 25 Člani EFPIA, ki sodelujejo v projektih Skupnega podjetja IMI, so prve izjave o stvarnih prispevkih predložili februarja 2012, potem ko je upravni odbor 11. novembra 2011 odobril metodologijo.
The Coordinated IAS-IAC Strategic Audit Plan for 2012-2014 was approved by the Governing Board on 3 November 2011. 
Odstavki od 26 do 28 Usklajeni strateški revizijski načrt za obdobje med letoma 2012 in 2014, ki sta ga pripravila služba Komisije za notranjo revizijo in oddelek za notranjo revizijo, je upravni odbor odobril 3. novembra 2011.
This was based on a comprehensive risk assessment exercise carried out jointly by the IAS and IMI JU’s Internal Audit Capability and finalised in September 2011. 
To je temeljilo na obsežni oceni tveganja, ki sta jo skupaj izvedla služba Komisije za notranjo revizijo in oddelek za notranjo revizijo Skupnega podjetja IMI ter ki je bila dokončana septembra 2011.
Throughout 2011, the Internal Audit Capability within IMI JU also carried out a number of internal audit consultancy engagements in relation to the development and strengthening of IMI JU’s governance, internal control and risk management systems and processes. 
V letu 2011 je oddelek za notranjo revizijo Skupnega podjetja IMI opravil tudi številna posvetovanja v okviru notranje revizije v zvezi z razvojem in izboljšanjem vodenja Skupnega podjetja IMI ter njegovih sistemov in postopkov notranjega kontroliranja in obvladovanja tveganj.
The first internal audit by the Internal Audit Service of the European Commission was carried out during the second quarter of 2012 with the final report being issued and submitted to the Executive Director and the Governing Board in July. 
Služba Evropske komisije za notranjo revizijo je prvo notranjo revizijo opravila v drugem četrtletju leta 2012, končno poročilo pa objavila julija, ko ga je predložila izvršnemu direktorju in upravnemu odboru.
This comprehensive internal audit exercise focused on the negotiations, grant agreement preparations and pre-financing sub-processes of IMI JU. 
Pri tej obsežni notranji reviziji je bil poudarek na pogajanjih, pripravah na sporazume o donacijah in predhodnem financiranju podprocesov Skupnega podjetja IMI.
The role of internal audit in IMI JU’s financial rules will also be duly amended to reflect the requirements of the model financial regulation for Public Private Partnerships expected to be introduced by the European Commission in 2013. 
Vloga notranje revizije v finančnih pravilih Skupnega podjetja IMI bo tudi ustrezno spremenjena, da bo odražala zahteve vzorčne finančne uredbe za javno-zasebna partnerstva, ki naj bi jo Evropska komisija sprejela leta 2013.
Paragraph 29 The provisions set out in the revised model Grant Agreement approved by the Governing Board on 11 November 2011 with regard to the audit of EFPIA companies’ in-kind contributions are in line with the parameters set out in Articles 12(4) and 12(5) of the Council Regulation (EC) No 73/2008 setting up IMI JU. 
Odstavek 29 Določbe iz popravljenega vzorčnega sporazuma o donacijah, ki ga je upravni odbor odobril 11. novembra 2011 v zvezi z revizijo stvarnih prispevkov podjetij EFPIA, so v skladu s parametri, določenimi v členih 12(4) in 12(5) Uredbe Sveta 73/2008 o ustanovitvi Skupnega podjetja IMI.
Nevertheless, as this is fundamentally a question of principle, the advice of the European Commission is now being sought on the rights of the European Court of Auditors to audit in-kind contributions of EFPIA companies who are not recipients of IMI JU funding. 
Ker pa gre v bistvu za načelno vprašanje, se je za nasvet povprašalo Evropsko komisijo o tem, ali ima Evropsko računsko sodišče pravico do revidiranja stvarnih prispevkov podjetij EFPIA, ki niso prejemniki financiranja Skupnega podjetja IMI.
Both have since been finalised and were in place by the first quarter of 2012. 
Od takrat sta bila oba načrta dokončana in uvedena v prvem četrtletju leta 2012.
Paragraph 32 Ex-post audits were launched in November 2011 and as at February 2012 there was no indication from the on-going audits that would have reasonably justified a reservation. 
Odstavek 32 Naknadne revizije so potekale novembra 2011, v februarju 2012 pa iz nobene revizije, ki je potekala, ni bilo razvidno, da bi bil pridržek razumno upravičen. SL
16.12.2016 Official Journal of the European Union C 473/47 EN REPORT on the annual accounts of the Fuel Cells and Hydrogen Joint Undertaking for the financial year 2015, together with the Joint UndertakingŐs reply (2016/C 473/06) CONTENTS INTRODUCTION........................................................ INFORMATIONINSUPPORTOFTHESTATEMENTOFASSURANCE ............... 
7–14 Mnenjeozanesljivostizaključnegaračuna..................................
Implementationofthe2015budget ...................................... 
12 Mnenje o zakonitosti in pravilnosti transakcij, povezanih z zaključnim računom . . . . .
OTHERMATTERS....................................................... 
22–26 Ključnekontroleinnadzornisistemi ......................................
Anti-FraudStrategy ................................................... 
22 Strategijazabojprotigoljufijam .........................................
Conflictsofinterest................................................... 
26 SPREMLJANJEUPOŠTEVANJAPRIPOMBIZPREJŠNJIHLET .......................
ANNEX .......................................................................... 
27 Navzkrižjainteresov...................................................
EN C 473/48 Official Journal of the European Union 16.12.2016 INTRODUCTION 1. 
SL C 473/58 Uradni list Evropske unije 16.12.2016 UVOD 1.
The Joint Undertaking for the implementation of the Joint Technology Initiative on Fuel Cells and Hydrogen (FCH Joint Undertaking), located in Brussels, was set up in May 2008 (1) for the period up to 31 December 2017 and was granted its financial autonomy on 15 November 2010. 
Skupno podjetje za izvajanje skupne tehnološke pobude za inovativna zdravila (v nadaljnjem besedilu: Skupno podjetje IMI) s sedežem v Bruslju je bilo ustanovljeno decembra 2007 (1) za obdobje desetih let. Samostojno je začelo poslovati 16. novembra 2009.
In May 2014 (2), the Council repealed the original Regulation and extended the lifetime of the Joint Undertaking, referred to as the ÔFuel Cells and Hydrogen 2 Joint UndertakingŐ (FCH 2 Joint Undertaking) (3), under the Horizon 2020 framework programme for research and innovation (4) for the period up to 31 December 2024. 
Svet je maja 2014 (2) razveljavil prvotno uredbo in Skupno podjetje, imenovano „Skupno podjetje za pobudo za inovativna zdravila 2“ (Skupno podjetje IMI 2) (3) pooblastil za izvajanje novih nalog v okviru okvirnega programa za raziskave in inovacije Obzorje 2020 (4) ter podaljšal življenjsko dobo Skupnega podjetja za obdobje do 31. decembra 2024.
The members of the Joint Undertaking are the European Union (EU), represented by the European Commission, the Industry Grouping (Hydrogen Europe (7)) and the Research Grouping (New European Research Grouping on Fuel Cells and Hydrogen (N.ERGHY)). 
Ustanovni članici Skupnega podjetja sta Evropska unija (EU), ki jo zastopa Komisija, in Evropska federacija farmacevtske industrije in združenj (EFPIA). Programu se lahko pridružijo tudi drugi člani in pridruženi partnerji.
The maximum EU contribution from Horizon 2020 to the activities of the FCH 2 Joint Undertaking is 665 million euro (of which administrative costs must not exceed 19 million euro (8)). 
Člani morajo enako prispevati k upravnim stroškom (ki za Skupno podjetje IMI 2 ne smejo presegati 85,2 milijona EUR).